CX717

CX717 is a drug developed by Cortex Pharmaceuticals designed to treat cognitive impairment, such as that caused by Alzheimer's disease. It is part of a class of drugs known as ampakines, which work by enhancing the function of the glutamate neurotransmitter system.

Mechanism of Action

CX717 works by modulating the AMPA receptor, a subtype of glutamate receptor in the brain. It enhances the activity of this receptor, leading to increased excitatory transmission in the brain. This is believed to improve cognitive function, particularly in conditions where cognitive impairment is present.

Clinical Trials

CX717 has undergone several phases of clinical trials. Initial trials showed promise in improving cognitive function in both healthy volunteers and patients with Alzheimer's disease. However, later trials were less successful, with the drug failing to show significant benefits over placebo.

Side Effects

Common side effects of CX717 include headache, dizziness, and nausea. In rare cases, it can cause more serious side effects such as hallucinations and psychosis.

Future Research

Despite the mixed results in clinical trials, research into CX717 and other ampakines continues. These drugs have the potential to treat a wide range of cognitive disorders, from Alzheimer's disease to schizophrenia and ADHD. Further research is needed to fully understand their potential benefits and risks.

See Also

• AMPA receptor
• Alzheimer's disease
• Cortex Pharmaceuticals
• Glutamate
• Ampakines